Tourmaline Bio, Inc. (NASDAQ:TRML) Director Parvinder Thiara Acquires 1,000 Shares

Tourmaline Bio, Inc. (NASDAQ:TRML) Director Parvinder Thiara bought 1,000 shares of Tourmaline Bio stock in a transaction dated Friday, November 17th. The stock was purchased at an average price of $17.31 per share, with a total value of $17,310.00. Following the completion of the purchase, the director now owns 83,782 shares in the company, valued at $1,450,266.42. The purchase was disclosed in a filing with the SEC, which is available at this link.

Tourmaline Bio Price Performance

TRML stock opened at $17.65 on Tuesday. The stock has a market cap of $75.54 million, a price-to-earnings ratio of -1.18 and a beta of 2.26. Tourmaline Bio, Inc. has a 52-week low of $8.90 and a 52-week high of $32.90.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Guggenheim assumed coverage on Tourmaline Bio in a report on Tuesday, October 31st. They issued a “buy” rating and a $50.00 price target on the stock. Truist Financial initiated coverage on shares of Tourmaline Bio in a research report on Friday. They issued a “buy” rating and a $43.00 price target for the company. Finally, Piper Sandler assumed coverage on shares of Tourmaline Bio in a report on Wednesday, October 25th. They set an “overweight” rating and a $65.00 price objective on the stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.